GEMODIVEQ
Live / Applied — Third extension granted (statement of use) (as of 21 Nov 2025)
What this means for you
Not registered yet, but its 28 Aug 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98154552
- Mark type
- Stylized text
- Filed
- 28 Aug 2023
- Published for opposition
- 28 May 2024
- Attorney of record
- Andrea Christensen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of muscular dystrophy
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 22 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Nov 2025 — SOU EXTENSION 3 GRANTED
- 21 Nov 2025 — SOU EXTENSION 3 FILED
- 21 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Jun 2025 — SOU EXTENSION 2 GRANTED
- 04 Jun 2025 — SOU EXTENSION 2 FILED
- 04 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 17 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Dec 2024 — SOU EXTENSION 1 GRANTED
- 18 Dec 2024 — SOU EXTENSION 1 FILED
- 17 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 23 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 May 2024 — PUBLISHED FOR OPPOSITION